breast cancer

First prospective trial’s five-year results show excellent tumor control, minimal adverse effects, and preserved breast appearance Peer-Reviewed Publication The National Institutes for Quantum Science and Technology image: Typical dose distribution for carbon-ion radiotherapy in breast cancer and a representative case of right-sided breast cancer in a 61-year-old woman (T1cN0M0, tumor size 10 mm). Top panel: Carbon-ion […]

by University of Texas MD Anderson Cancer Center edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published in Nature Communications, identifies a powerful strategy to overcome drug resistance in breast cancer by simultaneously targeting two key

by Baylor College of Medicine edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source Credit: Pixabay/CC0 Public Domain Of all the types of breast cancer, triple negative breast cancer (TNBC) is the most aggressive and lacks specific therapies. TNBC is also more likely to metastasize, or travel through the bloodstream to

A standard cardiovascular treatment is reported to disable treatment-resistant breast cancer cells by directly blocking the Mcl-1 protein Peer-Reviewed Publication Korea University College of Medicine image: Pitavastatin binds and suppresses Mcl-1, targets cancer stem-like properties, triggers mitochondrial apoptosis, and restores paclitaxel sensitivity in triple-negative breast cancer models. view more  Credit: Professor Jae Hong Seo from Korea

by University of Cambridge edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes Credit: Unsplash/CC0 Public Domain A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-estrogen treatment for women with breast cancer, a new Cambridge-led trial has found. A low dose of megestrol acetate (a synthetic version of progesterone) has already

Download PDF Copy  Reviewed University of Texas M. D. Anderson Cancer CenterDec 26 2025 A new study published today in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer Center details a therapeutic vulnerability in patients with an aggressive subtype of triple-negative breast cancer. Led by Khandan Keyomarsi, Ph.D., professor of Experimental Radiation Oncology,

Megan Brooks December 18, 2025 A trio of large observational studies reported at the San Antonio Breast Cancer Symposium (SABCS) 2025 suggest that GLP-1 receptor agonists may improve outcomes in some women with breast cancer. Two studies reported an overall survival benefit of GLP-1 use in certain patients with breast cancer, including those with ductal carcinoma in situ

by Medical University of South Carolina edited by Stephanie Baum, reviewed by Robert Egan  Editors’ notes Credit: Anna Tarazevich from Pexels Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other breast cancers treatable with targeted therapies. Even when

Peer-Reviewed Publication UNIVERSITY OF CALIFORNIA – SAN DIEGO IMAGE: THESE IMAGES SHOW MOUSE MAMMARY ORGANOIDS BEFORE AND AFTER TREATMENT WITH A NEW THERAPY CREATED BY UC SAN DIEGO RESEARCHERS. ON THE LEFT, THE ORGANOIDS ARE WHOLE. AFTER TREATMENT, THEY BURST, INDICATING CELL DEATH. view more  CREDIT: KARL WILLERT/UC SAN DIEGO HEALTH SCIENCES Researchers at the University